Who Generates More Revenue? Biogen Inc. or Pharming Group N.V.

Revenue Showdown: Biogen Inc. vs. Pharming Group N.V.

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. From 2014 to 2023, Biogen Inc. has consistently outperformed Pharming Group N.V. in terms of revenue. Biogen's revenue peaked in 2019, reaching approximately $14.4 billion, while Pharming Group's highest revenue was around $245 million in 2023. This stark contrast highlights Biogen's dominance, with its revenue being nearly 60 times greater than Pharming's in 2023.

A Decade of Growth

Biogen's revenue growth has been robust, with a 48% increase from 2014 to 2019. However, a slight decline was observed post-2019, with a 32% drop by 2023. In contrast, Pharming Group showed a steady upward trend, with a remarkable 850% increase from 2014 to 2023. This growth trajectory suggests potential for Pharming, albeit from a much smaller base.